Comments
Loading...
Cytek Biosciences Analyst Ratings and Price Targets | NASDAQ:CTKB | Benzinga
Cytek Biosciences Inc has a consensus price target of $6 based on the ratings of 5 analysts. The high is $8 issued by Piper Sandler on March 4, 2025. The low is $3 issued by Goldman Sachs on May 12, 2025. The 3 most-recent analyst ratings were released by Goldman Sachs, Stephens & Co., and Piper Sandler on May 12, 2025, March 19, 2025, and March 4, 2025, respectively. With an average price target of $5.67 between Goldman Sachs, Stephens & Co., and Piper Sandler, there's an implied 100.24% upside for Cytek Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Stephens & Co.
Piper Sandler
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Cytek Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | 6.01% | Goldman Sachs | Matthew Sykes63% | $3.5 → $3 | Maintains | Sell | Get Alert |
| 03/19/2025 | Buy Now | 112.01% | Stephens & Co. | Mason Carrico38% | $6 → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 03/04/2025 | Buy Now | 182.69% | Piper Sandler | David Westenberg59% | $8.5 → $8 | Maintains | Overweight | Get Alert |
| 11/11/2024 | Buy Now | 200.35% | Piper Sandler | David Westenberg59% | $8 → $8.5 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 182.69% | Piper Sandler | David Westenberg59% | $8.5 → $8 | Maintains | Overweight | Get Alert |
| 05/13/2024 | Buy Now | 200.35% | Piper Sandler | David Westenberg59% | $10 → $8.5 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 253.36% | Piper Sandler | David Westenberg59% | $11 → $10 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 253.36% | Goldman Sachs | Matthew Sykes63% | $9 → $10 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 218.02% | Stephens & Co. | Mason Carrico38% | → $9 | Initiates | → Overweight | Get Alert |
| 11/09/2023 | Buy Now | 147.35% | Morgan Stanley | Tejas Savant50% | $8 → $7 | Maintains | Equal-Weight | Get Alert |
| 10/24/2023 | Buy Now | 182.69% | Morgan Stanley | Tejas Savant50% | $13 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 253.36% | Piper Sandler | David Westenberg59% | $15 → $10 | Maintains | Overweight | Get Alert |
| 07/19/2023 | Buy Now | — | Raymond James | Andrew Cooper53% | — | Initiates | → Market Perform | Get Alert |
| 05/11/2023 | Buy Now | 359.36% | Morgan Stanley | Tejas Savant50% | $14 → $13 | Maintains | Equal-Weight | Get Alert |
| 05/10/2023 | Buy Now | 324.03% | Goldman Sachs | Matthew Sykes63% | $14 → $12 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 430.04% | Piper Sandler | David Westenberg59% | $18 → $15 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 394.7% | Morgan Stanley | Tejas Savant50% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | 394.7% | Goldman Sachs | Matthew Sykes63% | $16 → $14 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | 465.37% | Piper Sandler | David Westenberg59% | $12 → $16 | Maintains | Overweight | Get Alert |
| 08/12/2022 | Buy Now | 430.04% | Morgan Stanley | Tejas Savant50% | $11 → $15 | Maintains | Equal-Weight | Get Alert |
| 08/11/2022 | Buy Now | 500.71% | Goldman Sachs | Matthew Sykes63% | $15 → $17 | Maintains | Buy | Get Alert |
| 07/14/2022 | Buy Now | 430.04% | Goldman Sachs | Matthew Sykes63% | $12 → $15 | Maintains | Buy | Get Alert |
| 05/16/2022 | Buy Now | 324.03% | Piper Sandler | David Westenberg59% | $17 → $12 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Cytek Biosciences (CTKB) stock?
The latest price target for Cytek Biosciences (NASDAQ:CTKB) was reported by Goldman Sachs on May 12, 2025. The analyst firm set a price target for $3.00 expecting CTKB to rise to within 12 months (a possible 6.01% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
The latest analyst rating for Cytek Biosciences (NASDAQ:CTKB) was provided by Goldman Sachs, and Cytek Biosciences maintained their sell rating.
When was the last upgrade for Cytek Biosciences (CTKB)?
There is no last upgrade for Cytek Biosciences
When was the last downgrade for Cytek Biosciences (CTKB)?
There is no last downgrade for Cytek Biosciences.
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $3.50 to $3.00. The current price Cytek Biosciences (CTKB) is trading at is $2.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
